我國(guó)是非小細(xì)胞肺癌高發(fā)國(guó)，非小細(xì)胞肺癌已經(jīng)逐漸成為嚴(yán)重危害我國(guó)居民健康的疾病之一。目前針對(duì)非小細(xì)胞肺癌的治療主要以化療為主，但由于患者易對(duì)化療藥物產(chǎn)生耐藥性，長(zhǎng)期療效一直不理想。目前國(guó)際上對(duì)非小細(xì)胞肺癌耐藥相關(guān)生物標(biāo)志物進(jìn)行了很多研究，涉及到臨床上多種不同類型的化療藥物，用來(lái)指導(dǎo)臨床上開展的個(gè)體化治療方案。針對(duì)目前臨床上常見的幾類化療藥物的耐藥標(biāo)志物進(jìn)行綜述，便于非小細(xì)胞肺癌患者個(gè)體化治療的開展

Non-small cell lung cancer (NSCLC) is highly occurred in China, which has become the major cancer influencing human health. Nowadays the standard treatment for NSCLC is chemotherapy, however, chemoresistance was more and more frequently found in many patients, which to result in bad prognosis.So, lots of research on chemoresistant biomarkers in NSCLC has been launched. These biomarkers refer to several types of chemotherapeutics which could guide the therapeutic schedule in clinical medicine selections. In this article we focus on analyzing several chemoresistant biomarkers which may play an important role in implementation of individualized treatment for NSCLC.